DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine : A multicentre retrospective study
Noguera Castells, Aleix (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Campillo-Marcos, Ignacio (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Davalos, Veronica (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
García-Prieto, Carlos A. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Valcárcel, David (Vall d'Hebron Institut d'Oncologia)
Molero, Antonieta (Vall d'Hebron Institut d'Oncologia)
Palomo Sanchís, Laura (Vall d'Hebron Institut d'Oncologia)
Gattermann, Norbert (Universitätsklinikum Düsseldorf)
Wulfert, Michael (Universitätsklinikum Düsseldorf)
Chaparro, Lorea (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Sole, F. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Cabezón, Marta (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Jiménez-Lorenzo, María J. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Xicoy, Blanca (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Zamora, Lurdes (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
De Stefano, Alessia (Università di Bologna)
Casalin, Irene (Università di Bologna)
Finelli, C. (IRCCS Azienda Ospedaliero-Universitaria di Bologna. Institute of Hematology "Seràgnoli")
Follo, Matilde Y. (Università di Bologna)
Esteller, M. (Universitat de Barcelona. Departament de Ciències Fisiològiques)

Date:	2024
Abstract:	Real-world data have revealed that a substantial portion of patients with myelodysplastic syndromes (MDS) does not respond to epigenetic therapy with hypomethylating agents (HMAs). The cellular and molecular reasons for this resistance to the demethylating agent and biomarkers that would be able to predict the treatment refractoriness are largely unknown. In this study, we shed light on this enigma by characterizing the epigenomic profiles of patients with MDS treated with azacitidine. Our approach provides a comprehensive view of the evolving DNA methylation architecture of the disease and holds great potential for advancing our understanding of MDS treatment responses to HMAs.
Grants:	Agencia Estatal de Investigación PID2021-125282OB-I00 Agència de Gestió d'Ajuts Universitaris i de Recerca 2021/SGR-01494
Note:	DV reports personal fees from BMS/Celgene, Amgen, Astellas, Agios, Grifols, Janssen, MSD, Novartis, Pfizer, Sanofi, Sobi and Takeda outside the submitted work. AM reports personal fees from Oryzon genomics and AstraZeneca; non-financial support from Novartis and Jazz pharmaceuticals outside the submitted work. LZ reports grants and personal fees from Celgene/BMS, Incyte, and Novartis outside the submitted work. CF declares research funding, advisory committees and speaker fees from Celgene BMS, advisory committees and speaker fees from Novartis and consultancy from Takeda. ME declares grants from Ferrer International and Incyte; and personal fees from Quimatryx, outside the submitted work. No disclosures were reported by the other authors.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Azacitidine ; DNA methylation ; Hypomethylating agents ; Myelodysplastic syndromes
Published in:	British Journal of Haematology, Vol. 204 Núm. 5 (may 2024) , p. 1838-1843, ISSN 1365-2141

DOI: 10.1111/bjh.19392

6 p, 3.7 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Josep Carreras Leukaemia Research Institute
Articles > Research articles
Articles > Published articles